FOLD

NEUTRALM&A

Amicus Therapeutics, Inc.

2026-03-24

Price

$14.41

-0.07%

Score6.0Priority

Signals5/8 DNA1/13 Act · 0/4 Risk

SentimentNEUTRALScore: 8

Volume0.8xvs 20d avg

Analysis

Amicus Therapeutics (FOLD) is exhibiting classic M&A arbitrage price action, completely ignoring the current RISK_OFF geopolitical panic. BioMarin has agreed to acquire the company for $14.50 per share in an all-cash transaction, anchoring FOLD's price at $14.41. Technical signals like QUIET_STORM and an exceptionally low 2.1% realized volatility confirm high-conviction institutional absorption as arbitrageurs lock in the remaining spread. In an environment where the VIX is spiking above 26, FOLD serves as a synthetic cash proxy, insulated from macro equity beta risk unless regulatory hurdles emerge.

Fired Signals

ALPHA MALEQUIET STORMSTEADY CLIMBGOLDEN CROSSPERFECT STACKBARGAIN HUNTER

Key Takeaways

FOLD is strictly an M&A arbitrage play, trading at $14.41 against a firm $14.50 all-cash buyout offer from BioMarin expected to close in Q2 2026.
The exceptionally low 2.1% volatility and positive relative strength vs. SPY (+5.6%) are direct results of the stock acting as a cash-proxy, ignoring the U.S.-Iran macro regime.
The primary risk is regulatory; the deal remains subject to Hart-Scott-Rodino (HSR) antitrust clearance, which is the only hurdle preventing the final 9-cent spread convergence.

← Back to 2026-03-24 View Full FOLD History →Yahoo Finance &nearr;